top of page

Value of Gene Therapies

THE VALUE OF GENE THERAPIES

Gene therapies are fundamentally different from medicines that are taken over the course of a patient’s entire lifetime to address the symptoms of disease. Today’s new transformational therapies are designed to target the source of many rare diseases at the genetic level often with one lasting dose. These differences make gene therapies ill-suited for the current tools that are used by payers to determine their cost effectiveness.  

As more innovative gene therapies progress toward – and achieve – FDA approval, we must bring new thinking to how they are valued. 

Getting the value equation right for gene therapies will have a real and tangible impact on patients’ ability to benefit from this game-changing field.

IGT is committed to educating stakeholders about the value of gene therapies, what it looks like to accurately and fully assess their value, and the consequences if we fall short.

To start, we worked with our council members to identify the most important elements of value to patients, the healthcare system, and society.

Asset 2_2x.png

THE MOST IMPORTANT ELEMENTS OF VALUE TO PATIENTS, THE HEALTHCARE SYSTEM, AND SOCIETY, INCLUDE:

DISEASE STATE FACTORS

Asset 2.png

Burden on Patient

Asset 2.png

Addressing an Unmet Medical/Clinical Need/Severity of Disease

Asset 2.png

Rarity of Disease 

Asset 2.png

Family and Caregiver Burden

TREATMENT FACTORS

Asset 2.png

Treatment Effects (Short- and Long-Term)

Asset 2.png

Lifetime Impact/Durability

Asset 2.png

Patient Reported Outcomes

SYSTEM IMPACT

Asset 2.png

Medical Costs (Direct/Indirect)

SOCIETAL IMPACT

Asset 2.png

Advancing Health Equity/Preventing Discrimination

Asset 2.png

Goodwill or the Value of Hope (Hope for families and physicians to treat their patients)

MORE RESOURCES:

bottom of page